The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
In silico repositioning of approved drugs for rare and neglected diseases
Open accessAbstract
One approach to speed up drug discovery is to examine new uses for existing approved drugs, so-called 'drug repositioning' or 'drug repurposing', which has become increasingly popular in recent years. Analysis of the literature reveals many examples of US Food and Drug Administration-approved drugs that are active against multiple targets (also termed promiscuity) that can also be used to therapeutic advantage for repositioning for other neglected and rare diseases. Using proof-of-principle examples, we suggest here that with current in silico technologies and databases of the structures and biological activities of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge for neglected or rare/orphan diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Thousands of chemical starting points for antimalarial lead identification
Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V. S., Kumar, V., Hasan, S., et al. (2010) · Nature · doi:10.1038/nature09107 · Cited by 996
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707305 · Cited by 703
Self-citationDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Chemical genetics of Plasmodium falciparum
Guiguemde, W. A., Shelat, A. A., Bouck, D., Duffy, S., Crowther, G. J., Davis, P. H., Smithson, D. C., Connelly, M., Clark, J., Zhu, F., et al. (2010) · Nature · doi:10.1038/nature09099 · Cited by 566
Clinical research for rare disease: Opportunities, challenges, and solutions
Griggs, R. C., Batshaw, M., Dunkle, M., Gopal-Srivastava, R., Kaye, E., Krischer, J., Nguyen, T., Paulus, K., & Merkel, P. A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.003 · Cited by 401
In silico pharmacology for drug discovery: applications to targets and beyond
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 365
Self-citationUnveiling the role of network and systems biology in drug discovery
Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.006 · Cited by 346
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
Kinnings, S. L., Liu, N., Buchmeier, N., Tonge, P. J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000423 · Cited by 319
An overview of the PubChem BioAssay resource
Wang, Y., Bolton, E., Dracheva, S., Karapetyan, K., Shoemaker, B. A., Suzek, T. O., Wang, J., Xiao, J., Zhang, J., & Bryant, S. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp965 · Cited by 295
A network view of disease and compound screening
Schadt, E. E., Friend, S. H., & Shaywitz, D. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2826 · Cited by 291
A clinical drug library screen identifies astemizole as an antimalarial agent
Chong, C. R., Chen, X., Shi, L., Liu, J. O., & Sullivan, D. J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio806 · Cited by 289
High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv
Ananthan, S., Faaleolea, E. R., Goldman, R. C., Hobrath, J. V., Kwong, C. D., Laughon, B. E., Maddry, J. A., Mehta, A., Rasmussen, L., Reynolds, R. C., et al. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.05.008 · Cited by 279
Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
Chiang, A. P., & Butte, A. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.103 · Cited by 268
Pathway Mapping Tools for Analysis of High Content Data
Ekins, S., Nikolsky, Y., Bugrim, A., Kirillov, E., & Nikolskaya, T. (2006) · High Content Screening · doi:10.1385/1-59745-217-3:319 · Cited by 255
Self-citationPoroikov, V. V., Filimonov, D. A., Borodina, Y. V., Lagunin, A. A., & Kos, A. (2000) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000383k · Cited by 254
Miller, S. C., Huang, R., Sakamuru, S., Shukla, S. J., Attene-Ramos, M. S., Shinn, P., Van Leer, D., Leister, W., Austin, C. P., & Xia, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.021 · Cited by 250
PROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
Boguski, M. S., Mandl, K. D., & Sukhatme, V. P. (2009) · Science · doi:10.1126/science.1169920 · Cited by 220
Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
Inhibition of Angiogenesis by the Antifungal Drug Itraconazole
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., & Liu, J. O. (2007) · ACS Chemical Biology · doi:10.1021/cb600362d · Cited by 210
Predicting ligand binding to proteins by affinity fingerprinting
Kauvar, L. M., Higgins, D. L., Villar, H. O., Sportsman, J. R., Engqvist-Goldstein, Å., Bukar, R., Bauer, K. E., Dilley, H., & Rocke, D. M. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90283-x · Cited by 208
Inhibiting transthyretin conformational changes that lead to amyloid fibril formation
Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., & Kelly, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12956 · Cited by 206
Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma
Namkoong, J., Shin, S.-S., Lee, H. J., Marín, Y. E., Wall, B. A., Goydos, J. S., & Chen, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3665 · Cited by 192
Biological spectra analysis: Linking biological activity profiles to molecular structure
Fliri, A. F., Loging, W. T., Thadeio, P. F., & Volkmann, R. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407790101 · Cited by 190
EKINS, S., NIKOLSKY, Y., & NIKOLSKAYA, T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.006 · Cited by 180
Self-citationPredicting ADME properties and side effects: the BioPrint approach.
Krejsa, C. M., Horvath, D., Rogalski, S. L., Penzotti, J. E., Mao, B., Barbosa, F., & Migeon, J. (2003) · PubMed · Cited by 176
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Peng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C. A., & Duan, W. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.10.015 · Cited by 173
Mapping Adverse Drug Reactions in Chemical Space
Scheiber, J., Jenkins, J. L., Sukuru, S. C. K., Bender, A., Mikhailov, D., Milik, M., Azzaoui, K., Whitebread, S., Hamon, J., Urban, L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801546k · Cited by 160
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore
Miller, J. R., Dunham, S., Mochalkin, I., Banotai, C., Bowman, M., Buist, S., Dunkle, B., Hanna, D., Harwood, H. J., Huband, M. D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811275106 · Cited by 159
Analysis of drug-induced effect patterns to link structure and side effects of medicines
Fliri, A. F., Loging, W. T., Thadeio, P. F., & Volkmann, R. A. (2005) · Nature Chemical Biology · doi:10.1038/nchembio747 · Cited by 158
Scheiber, J., Chen, B., Milik, M., Sukuru, S. C. K., Bender, A., Mikhailov, D., Whitebread, S., Hamon, J., Azzaoui, K., Urbán, L., et al. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800344p · Cited by 153
Antituberculosis activity of the molecular libraries screening center network library
Maddry, J. A., Ananthan, S., Goldman, R. C., Hobrath, J. V., Kwong, C. D., Maddox, C. B., Rasmussen, L. A., Reynolds, R. C., Secrist, J. A. I., Sosa, M. I., et al. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.07.006 · Cited by 151
Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms
Ekins, S., Bugrim, A. E., Brovold, L., Kirillov, E., Nikolsky, Y., Rakhmatulin, E. A., Sorokina, S. Y., Ryabov, A., Serebryiskaya, T., Melnikov, A., et al. (2006) · Xenobiotica · doi:10.1080/00498250600861660 · Cited by 150
Self-citationHohman, M. M., Gregory, K., Chibale, K., Smith, P. J., Ekins, S., & Bunin, B. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.015 · Cited by 148
Self-citationRapid Identification of P-glycoprotein Substrates and Inhibitors
Chang, C. K., Bahadduri, P. M., Polli, J. E., Swaan, P. W., & Ekins, S. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012351 · Cited by 148
Self-citationPredicting undesirable drug interactions with promiscuous proteins in silico
Ekins, S. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03008-3 · Cited by 134
Self-citationNovel paradigms for drug discovery: computational multitarget screening
Jenwitheesuk, E., HORST, J., Rivas, K. L., VanVoorhis, W. C., & Samudrala, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.007 · Cited by 133
A novel method for generation of signature networks as biomarkers from complex high throughput data
Nikolsky, Y., Ekins, S., Nikolskaya, T., & Bugrim, A. E. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.02.004 · Cited by 133
Self-citationTargeting Isoprenoid Biosynthesis for Drug Discovery: Bench to Bedside
Oldfield, E. (2010) · Accounts of Chemical Research · doi:10.1021/ar100026v · Cited by 129
Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance
de Carvalho, L. P. S., Lin, G., Jiang, X., & Nathan, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9010719 · Cited by 129
A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury
Ekins, S., Williams, A. J., & Xu, J. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035113 · Cited by 129
Self-citationThe importance of discerning shape in molecular pharmacology
Kortagere, S., Krasowski, M. D., & Ekins, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.001 · Cited by 124
Self-citationA COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT
Ekins, S., Andreyev, S., Ryabov, A., Kirillov, E., Rakhmatulin, E. A., Sorokina, S. Y., Bugrim, A. E., & Nikolskaya, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008458 · Cited by 117
Self-citationNetwork analysis of FDA approved drugs and their targets
Ma’ayan, A., Jenkins, S. L., Goldfarb, J., & Iyengar, R. (2007) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20002 · Cited by 117
Priming the antimalarial pipeline
Fidock, D. A. (2010) · Nature · doi:10.1038/465297a · Cited by 116
Prediction of Adverse Drug Reactions Using Decision Tree Modeling
Hammann, F., Gutmann, H., Vogt, N., Helma, C., & Drewe, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.248 · Cited by 115
Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer
Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H.-E. C., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq457 · Cited by 115
Ou, H. C., Cunningham, L. L., Francis, S. P., Brandon, C. S., Simon, J. A., Raible, D. W., & Rubel, E. W. (2009) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-009-0158-y · Cited by 114
Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR
Ekins, S., Kortagere, S., Iyer, M., Reschly, E. J., Lill, M. A., Redinbo, M. R., & Krasowski, M. D. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000594 · Cited by 110
Self-citationRepositioning of an existing drug for the neglected tropical disease Onchocerciasis
Gloeckner, C., Garner, A. L., Mersha, F. B., Oksov, Y., Tricoche, N., Eubanks, L. M., Lustigman, S., Kaufmann, G. F., & Janda, K. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915125107 · Cited by 107
Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei
Mackey, Z. B., Baca, A. M., Mallari, J. P., Apsel, B., Shelat, A. A., Hansell, E. J., Chiang, P. K., Wolff, B. E., Guy, R. K., Williams, J. A., et al. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00389.x · Cited by 106
Miguel, D. C., Yokoyama-Yasunaka, J. K. U., Andreoli, W. K., Mortara, R. A., & Uliana, S. R. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm219 · Cited by 104
Roth, B. L., Lopez, E., Beischel, S., Westkaemper, R. B., & Evans, J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.004 · Cited by 103
Metz, J. T., & Hajduk, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.166 · Cited by 100
Computer Applications in Pharmaceutical Research and Development
(2006) · Wiley eBooks · doi:10.1002/0470037237 · Cited by 100
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
Bisson, W. H., Cheltsov, A. V., Bruey-Sédano, N., Lin, B., Chen, J., Goldberger, N. E., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609752104 · Cited by 99
Global Bayesian Models for the Prioritization of Antitubercular Agents
Prathipati, P., Ma, N. L., & Keller, T. H. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800143n · Cited by 96
Rising standards for tuberculosis drug development
Balganesh, T. S., Alzari, P. M., & Cole, S. T. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.08.001 · Cited by 94
Identification of Type 1 Inosine Monophosphate Dehydrogenase as an Antiangiogenic Drug Target
Chong, C. R., Qian, D. Z., Pan, F., Wei, Y., Пили, Р., Sullivan, D. J., & Liu, J. O. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051225t · Cited by 93
High‐order combination effects and biological robustness
Lehár, J., Krueger, A., Zimmermann, G. R., & Borisy, A. A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.51 · Cited by 93
Computational Models for Drug Inhibition of the Human Apical Sodium-Dependent Bile Acid Transporter
Zheng, X., Ekins, S., Raufman, J., & Polli, J. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900163d · Cited by 92
Self-citationShahinas, D., Liang, M., Datti, A., & Pillai, D. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901796s · Cited by 91
Fliri, A. F. J., Loging, W., Thadeio, P. F., & Volkmann, R. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050494g · Cited by 91
New anti-tuberculosis agents amongst known drugs
Lougheed, K. E. A., Taylor, D. L., Osborne, S. A., Bryans, J. S., & Buxton, R. S. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.07.002 · Cited by 89
Chemical target and pathway toxicity mechanisms defined in primary human cell systems
Berg, E. L., Yang, J. B., Melrose, J. E., Nguyen, D., Privat, S., Rosler, E. S., Kunkel, E. J., & Ekins, S. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.10.001 · Cited by 84
Self-citationComputational databases, pathway and cheminformatics tools for tuberculosis drug discovery
Ekins, S., Freundlich, J. S., Choi, I., Sarker, M., & Talcott, C. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.10.005 · Cited by 83
Self-citation(2005) · Wiley eBooks · doi:10.1002/0471728780 · Cited by 83
A collaborative database and computational models for tuberculosis drug discovery
Ekins, S., Bradford, J., Dole, K., Spektor, A. C., Gregory, K., Blondeau, D., Hohman, M. M., & Bunin, B. A. (2010) · Molecular BioSystems · doi:10.1039/b917766c · Cited by 82
Self-citationInternet-based tools for communication and collaboration in chemistry
Williams, A. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.03.015 · Cited by 78
Self-citationKrasowski, M. D., Pizon, A. F., Siam, M. G., Giannoutsos, S., Iyer, M., & Ekins, S. (2009) · BMC Emergency Medicine · doi:10.1186/1471-227x-9-5 · Cited by 74
Self-citationEkins, S., Kaneko, T., Lipinski, C. A., Bradford, J., Dole, K., Spektor, A. C., Gregory, K., Blondeau, D., Ernst, S. D., Yang, J. J., et al. (2010) · Molecular BioSystems · doi:10.1039/c0mb00104j · Cited by 72
Self-citationChemical-Genetic Screen Identifies Riluzole as an Enhancer of Wnt/β-catenin Signaling in Melanoma
Biechele, T. L., Camp, N. D., Fass, D. M., Kulikauskas, R. M., Robin, N. C., White, B. D., Taraska, C. M., Moore, E. C., Muster, J., Karmacharya, R., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.08.012 · Cited by 69
Screening the receptorome: an efficient approach for drug discovery and target validation
Strachan, R. T., Ferrara, G., & Roth, B. L. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.012 · Cited by 67
Gad, S. C. (1994) · Cited by 65
Ekins, S., & Williams, A. J. (2009) · Lab on a Chip · doi:10.1039/b917760b · Cited by 65
Self-citationSystems-ADME/Tox: Resources and network approaches
Ekins, S. (2005) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2005.05.005 · Cited by 64
Self-citationIn Vitro and Pharmacophore-Based Discovery of Novel hPEPT1 Inhibitors
Ekins, S., Johnston, J. S., Bahadduri, P. M., D’Souza, V. M., Ray, A., Chang, C. K., & Swaan, P. W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-2505-y · Cited by 62
Self-citationComputer Applications In Pharmaceutical Research And Development
Ekins, S. (2017) · Cited by 60
Self-citationEssential Metabolites of Mycobacterium tuberculosis and Their Mimics
Lamichhane, G., Freundlich, J. S., Ekins, S., Wickramaratne, N. A., Nolan, S. T., & Bishai, W. R. (2011) · mBio · doi:10.1128/mbio.00301-10 · Cited by 60
Self-citationA chemogenomic approach to drug discovery: focus on cardiovascular diseases
Cases, M., & Mestres, J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.010 · Cited by 60
Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)
Jones, D. R., Ekins, S., Li, L., & Hall, S. D. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014613 · Cited by 60
Self-citationMassively Parallel Screening of the Receptorome
Jensen, N., & Roth, B. L. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708784911483 · Cited by 57
Drug development for orphan diseases in the context of personalized medicine
Brewer, G. J. (2009) · Translational research · doi:10.1016/j.trsl.2009.03.008 · Cited by 57
Integrated in Silico−in Vitro Strategy for Addressing Cytochrome P450 3A4 Time-Dependent Inhibition
Zientek, M. A., Stoner, C. L., Ayscue, R. R., Klug-McLeod, J. L., Jiang, Y., West, M., Collins, C., & Ekins, S. (2010) · Chemical Research in Toxicology · doi:10.1021/tx900417f · Cited by 52
Self-citationRepurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii
Chopra, S., Torres-Ortiz, M., Hokama, L. A., Madrid, P. B., Tanga, M. J., Mortelmans, K. E., Kodukula, K., & Galande, A. K. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq353 · Cited by 51
Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease
Masuda, N., Peng, Q., Li, Q., Jiang, M., Liang, Y., Wang, X., Zhao, M., Wang, W., Ross, C. A., & Duan, W. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.014 · Cited by 51
Downey, A. S., Chong, C. R., Graczyk, T. K., & Sullivan, D. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00207-08 · Cited by 51
Krasowski, M. D., Siam, M. G., Iyer, M., & Ekins, S. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819c1b83 · Cited by 44
Self-citationChemoinformatic Methods for Predicting Interference in Drug of Abuse/Toxicology Immunoassays
Krasowski, M. D., Siam, M. G., Iyer, M., Pizon, A. F., Giannoutsos, S., & Ekins, S. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118638 · Cited by 44
Self-citationAn integrated dataset for in silico drug discovery
Cockell, S., Weile, J., Lord, P., Wipat, C., Andriychenko, D., Pocock, M., Wilkinson, D. J., Young, M. P., & Wipat, A. (2010) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2010-116 · Cited by 43
Pan, Y., Li, L., Kim, G., Ekins, S., Wang, H., & Swaan, P. W. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035808 · Cited by 42
Self-citationIdentification of Inhibitors of ABCG2 by a Bioluminescence Imaging–Based High-Throughput Assay
Zhang, Y., Byun, Y., Ren, Y. R., Liu, J. O., Laterra, J., & Pomper, M. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4866 · Cited by 40
Diao, L., Ekins, S., & Polli, J. E. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9905-3 · Cited by 38
Self-citationWhen pharmaceutical companies publish large datasets: an abundance of riches or fool's gold?
Ekins, S., & Williams, A. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.08.010 · Cited by 38
Self-citationWang, X., Douglas, S. D., Lai, J.-P., Tuluc, F., Tebas, P., & Ho, W. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9059-6 · Cited by 35
Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery
Walsh, C. T., & Fischbach, M. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813405106 · Cited by 33
IDMap: facilitating the detection of potential leads with therapeutic targets
Ha, S., Seo, Y.-J., Kwon, M.-S., Chang, B.-H., Han, C.-K., & Yoon, J. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn138 · Cited by 33
Diao, L., Ekins, S., & Polli, J. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100226q · Cited by 32
Self-citationSenkovich, O., Bhatia, V., Garg, N. J., & Chattopadhyay, D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3234-3238.2005 · Cited by 31
LASSO—ligand activity by surface similarity order: a new tool for ligand based virtual screening
Reid, D., Sadjad, B. S., Zsoldos, Z., & Simon, A. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9164-5 · Cited by 30
Concept-Based Semi-Automatic Classification of Drugs
Gurulingappa, H., Kolářik, C., Hofmann‐Apitius, M., & Fluck, J. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9000844 · Cited by 28
A large-scale computational approach to drug repositioning.
Li, Y. Y., An, J., & Jones, S. J. M. (2006) · PubMed · Cited by 27
An integrated dataset for in silico drug discovery
Cockell, S., Weile, J., Lord, P., Wipat, C., Andriychenko, D., Pocock, M., Wilkinson, D. J., Young, M. P., & Wipat, A. (2010) · PubMed · doi:10.2390/biecoll-jib-2010-116 · Cited by 26
Systems Biology: Applications in Drug Discovery
Ekins, S., Bugrim, A. E., Nikolsky, Y., & Nikolskaya, T. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse005 · Cited by 25
Self-citationEkins, S., & Williams, A. J. (2010) · MedChemComm · doi:10.1039/c0md00129e · Cited by 23
Self-citationAPT drug R&D: the right active ingredient in the right presentation for the right therapeutic use
Cavalla, D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2981 · Cited by 22
Substance P Receptor Antagonism for Treatment of Cryptosporidiosis in Immunosuppressed Mice
Robinson, P., Martin, P. E., Garza, A., D'Souza, M., Mastrangelo, M.-A. A., & Tweardy, D. J. (2008) · Journal of Parasitology · doi:10.1645/ge-1458.1 · Cited by 20
Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) Database
Ekins, S., Hohman, M. M., & Bunin, B. A. (2011) · Wiley eBooks · doi:10.1002/9781118026038.ch21 · Cited by 16
Self-citationGlybenclamide: An antidiabetic with in vivo antithrombotic activity
Ting, H. J., & Khasawneh, F. T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.009 · Cited by 16
Cited by
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Shifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Metadata
- Authors
- Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 16
- Issue
- 7-8
- Pages
- 298-310
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2114445615
- Cited by
- 288
- References
- 121
- FWCI
- 24.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.